On topic speculationFirst off I spent over an hour or more putting down thoughts re the meeting delays and when I tried to post Stockhouse crashed again because it couldn't handle the volume. Extremely frustrating and it happens many times. Most of the time when I am building a post I continuously copy and paste to Word as a back up. This time I didn't and it was all lost.
Frustrating but no big deal because it was just one of my rambles.
So there have been many excellent posts on Agora, IV (F6) and SH regarding speculations on the deferral of the meeting to Dec 15th.
So here is a much-reduced version of my lost post.
So what do we know?
- Both (Zenith and RVX) AGMs were switched to Dec 15th, a 2 month delay.
- There was a very significant run up in share price and volume of RVX starting on Sept 13th.
- At the NYC R & D update Don apparently stated a new licensing deal would be announced soon.
- I believe, in a previous update, Don had stated the next partnership deal would not involve shares (no dilution).
So some thoughts;
- There should be no reason to delay the AGMs.
- They could have held the standard AGM meeting appointing the boards, presenting the financials and other standard issues.
- If something is happening that requires a special vote it does not have to be part of the AGM.
- However, if the meeting requires bringing together the people required at the AGM to also be at the "whatever it is vote" then it could be more cost efficient to do it at one meeting.
Status of trials.
- As we all know BETonMACE is moving forward at an expected pace and we won't know anything until the futility analysis in 2017.
- The zen3694 mCRPC trial will complete it's 5th level of dosing complete at 11/2.
- Other trials seem to be very much in 2017.
- Therefore, I do not expect that whatever is happening to be related to trial results.
However, it appears that the BET inhibition field in cancer is heating up as per posts by BDAZ and Masila (e.g. Gilead and Pfizer (Medication)). Given that Zenith has an 8 year lead in BET inhibitors and is now well into it’s zen3694 mCRPC trial this could have evoked some attention by companies trying to catch up in this field. Since the trial is not double blind we will have results soon so perhaps a suitor is willing to jump in now at a reasonable price for the zen3694 given all of the pre trial data.
So since notification needs to flow to investors by Nov 15th we’ll know soon.
It would seem that the most obvious guess is a licensing deal.
It would also seem that the value of the deal is already priced in at the $2.00 level.
Oh well, just thinking out loud.
GLTA
Toinv